Pacira BioSciences to Present at the 44th Annual J.P. Morgan Healthcare Conferences

Pacira BioSciences (Nasdaq: PCRX) will present at the 44th Annual J.P.

Rhea-AI Summary

Pacira BioSciences (Nasdaq: PCRX) will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 11:15 AM PST (2:15 PM EST). Live audio will be available via the company’s Events page at investor.pacira.com. A replay of the webcast will be accessible for two weeks following the presentation.

This presentation offers investors and analysts direct access to management commentary and company updates on Pacira’s non-opioid pain therapy commercial and development priorities.

Argus Jan 7 session

+2.73% close to close Open Argus

Details

News Market Reaction – PCRX

On Jan 7, the day this news came out, PCRX closed 2.73% above the previous close.

Data tracked by StockTitan Argus for the Jan 7 session.

Market Context

This announcement highlights Pacira BioSciences’ planned presentation at the 44th J.P. Morgan Health...

Analysis

This announcement highlights Pacira BioSciences’ planned presentation at the 44th J.P. Morgan Healthcare Conference on January 14, 2026, with a live webcast and two-week replay. In context of recent clinical data, research collaborations, and governance and litigation updates, the conference slot offers another platform for management to communicate strategy and progress. Investors may watch for any new information shared during the presentation and how it relates to prior disclosures.

Key Figures

Conference edition: 44th Annual Presentation time PST: 11:15 AM PST Presentation time EST: 2:15 PM EST +1 more

Conference edition

44th Annual

J.P. Morgan Healthcare Conference

Presentation time PST

11:15 AM PST

Conference session on January 14, 2026

Presentation time EST

2:15 PM EST

Simultaneous session time in U.S. Eastern Time

Webcast replay period

Two weeks

Replay availability following the event

Historical Context

5 past events · Latest: Dec 30

5 events

1. Dec 30

   Board nomination

   24h Move

   +0.0%

   Investor group announced intent to nominate three director candidates.

2. Dec 18

   Research collaboration

   24h Move

   -2.5%

   Joined PROBE Consortium to advance osteoarthritis research using large OA datasets.

3. Dec 03

   Inducement grants

   24h Move

   +0.5%

   Granted 2,200 RSUs to new hires under inducement plan with time-based vesting.

4. Dec 02

   Clinical study data

   24h Move

   +1.6%

   12‑month pilot showed better pain and function outcomes for iovera° vs RFA.

5. Nov 26

   Patent litigation

   24h Move

   -1.0%

   Filed EXPAREL patent infringement lawsuits against two counterparties.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BRISBANE, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will present at the 44^th Annual J.P. Morgan Healthcare Conference at 11:15 AM PST (2:15 PM EST) on Wednesday, January 14, 2026. Live audio of the event can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event.

About Pacira
Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL^® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA^® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and iovera_®º, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The company is also advancing a pipeline of clinical-stage assets for musculoskeletal pain and adjacencies, its most advanced product candidate, PCRX-201 (enekinragene inzadenovec), a novel locally administered gene therapy in Phase 2 clinical development for osteoarthritis of the knee. To learn more about Pacira, visit www.pacira.com.

Company Contact:
Pacira BioSciences, Inc.
Christian Pedetti
(973) 254-4387
Christian.pedetti@pacira.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Pacira (PCRX) present at the J.P. Morgan Healthcare Conference in 2026?

Pacira will present on January 14, 2026 at 11:15 AM PST (2:15 PM EST).

How can I listen to Pacira (PCRX) live at the January 14, 2026 presentation?

Live audio is available on Pacira’s Events page at investor.pacira.com.

Will Pacira (PCRX) provide a replay of the J.P. Morgan presentation?

Yes. A replay of the webcast will be available for two weeks after the event.

What topics will Pacira (PCRX) cover in the January 14, 2026 presentation?

The company will discuss business and development updates related to its non-opioid pain therapies and company outlook.

Is the Pacira (PCRX) J.P. Morgan presentation open to all investors?

Yes. The live audio is publicly accessible via the company’s investor Events page.